BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
What similarly acting projects are still unpartnered?
After a conference lacking the wow factor, biotech winners and losers emerge.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.